Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Rhythm Pharmaceuticals, Raises Price Target to $28

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $26 to $28.
byBenzinga Newsdesk
March 2, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Equal-Weight and raises the price target from $26 to $28.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Rite Initiates Voluntary Chapter 11 Process to Implement a Consensual Financial Restructuring, Receives Commitment for $3.45B in New Financing, Taps Jeffrey S. Stein as CEO and Director Succeeding Interim CEO Elizabeth (“Busy”) Burr

By Benzinga Newsdesk
October 16, 3:27 AM
Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial

RAD